Skip to main content

Table 3 Clinicopathological and immunohistochemical parameters in relation to nuclear GLI1 immunoreactivity

From: Expression of the glioma-associated oncogene homolog (GLI) 1in human breast cancer is associated with unfavourable overall survival

Variable

Categorization

GLI1 nuclear immunoreactivityb 0–6 vs 7–12

  

n analyzable

low

high

P c

Clinicopathological data:

Tumour stagea

 

pT1

57

34

23

<0.001

 

pT2

87

19

68

 
 

pT3

12

3

9

 
 

pT4

28

8

20

 

Lymph node status

 

pN0

78

36

42

0.027

 

pN1-3

100

30

70

 

Histologic grade

 

G1

21

10

11

0.191

 

G2

81

29

52

 
 

G3

82

25

57

 

Multifocality

 

unifocal tumour

161

57

104

0.844

 

multifocal tumour

24

8

16

 

Histologic type

 

ductal

152

57

95

0.312

 

lobular

14

3

11

 
 

other

17

5

2

 

Immunohistochemistry (IHC):

Oestrogen receptor status

 

negative

53

19

34

0.484

 

positive

96

29

67

 

Progesterone receptor status

 

negative

109

33

76

0.266

 

positive

51

20

31

 

HER2 status

 

weak (0–2+)

132

45

87

0.847

 

strong (3+)

31

10

21

 
  1. aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
  2. bGLI1 nuclear immunoreactivity: low = IRS 0–6, high = IRS 7–12
  3. cFisher's exact test (two-sided), bold face representing significant data (P < 0.05)